Vuno
VUNO is a Seoul-based medical AI company that develops FDA-approved deep learning software for radiology (chest X-ray, fundus), cardiac arrest prediction (DeepCARS), and consumer chronic disease management (HATIV), selling to hospitals and healthcare systems globally.
- Company typePrivate
- Founded2014
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B and B2C
- OfferingSoftware
What Vuno does
VUNO Inc. is a Seoul-based, KOSDAQ-listed medical AI company founded in 2014 that develops deep learning-based software for diagnostic decision support and clinical monitoring. The company's core platform analyzes medical imaging (chest X-ray, fundus, CT, MRI), digital pathology slides, biosignals (ECG, vital signs), and speech to deliver AI medical devices marketed under the VUNO Med brand and a consumer health platform under the VUNO Care brand.
The product portfolio comprises four primary offerings: VUNO Med-Chest X-ray (abnormality detection in chest radiographs), VUNO Med-Fundus AI (12-class fundus finding classification), VUNO Med-DeepCARS (24-hour cardiac arrest risk prediction from vital signs, FDA-approved with a validated 21% reduction in cardiac arrest in a secondary hospital study), and VUNO Care-HATIV, a chronic disease management platform that extends clinical monitoring into the consumer health domain via VUNO Mall and Naver Smart Store. VUNO holds FDA approvals for multiple AI medical devices and Korea MFDS clearances, supported by ISO/IEC 27001:2022 and ISO/IEC 27701:2019 certifications.
VUNO monetizes through B2B sales of medical AI software to hospitals and healthcare systems (quote-based annual licensing), B2C subscriptions and unit sales via its consumer health e-commerce storefronts, and international licensing/partnership revenue. Distribution combines direct enterprise sales in Korea with channel partnerships in Europe (Contextflow in Austria, Mesalvo in Germany targeting 900+ hospitals) and a US subsidiary (VUNO Med Inc.) for the American market. Reported Q1 2026 revenue was 61억 won (6.1 billion KRW), with cumulative disclosed funding of approximately $37M across multiple rounds between 2014 and 2026.
Vuno firmographics
Firmographics- Name
- Vuno
- Legal name
- 주식회사 뷰노
- Website
- https://vuno.co
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- VUNO is a Seoul-based medical AI company that develops FDA-approved deep learning software for radiology (chest X-ray, fundus), cardiac arrest prediction (DeepCARS), and consumer chronic disease management (HATIV), selling to hospitals and healthcare systems globally.
- Ownership category
- akta.pro rank
Vuno industry classification
Industry- Product category
- Medical AI Software
- NAICS
- Software Publishers (5132), Custom Computer Programming Services (541511), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Healthcare & Wellness Personalization (HDAAAGAI)
Keywords
Where Vuno is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Vuno business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- VUNO Med (Medical Device AI Software): Sale of FDA-approved and Korea MFDS-cleared AI medical devices (Chest X-ray, Fundus AI, DeepCARS) to hospitals and healthcare systems. Revenue generated from device licensing, software subscriptions, and potentially one-time device sales.
- VUNO Care - HATIV (Consumer Health Platform): Chronic disease management platform sold directly to consumers via e-commerce (VUNO Mall, Naver Smart Store). Subscription or unit-based pricing for personal health monitoring devices and services.
- International Licensing and Partnership Revenue: Revenue from international market expansion through licensing agreements, partnerships with European distributors (Contextflow, Mesalvo), and potential royalty arrangements as DeepCARS and other solutions enter new geographies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | B2B Medical AI Solutions (VUNO Med) |
| Subscription | Monthly | Consumer Health Platform (VUNO Care/HATIV) |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
Vuno product offering
Product offeringCore offering
VUNO develops and sells deep learning-based medical AI software products under two brands: VUNO Med (B2B medical device AI for hospitals including Chest X-ray analysis, Fundus AI, and DeepCARS cardiac arrest prediction) and VUNO Care (B2C consumer health platform HATIV for chronic disease management). The company generates revenue through software/device licensing and subscriptions to clinical and consumer health monitoring solutions that analyze medical imaging, biosignals, and digital pathology data.
Product overview
Vuno offers a unified medical AI platform with two main product lines: VUNO Med and VUNO Care. VUNO Med comprises diagnostic AI solutions including Chest X-ray (AI-powered chest X-ray analysis), Fundus AI (fundus image analysis), and DeepCARS (cardiac arrest prediction using vital signs/ECG). VUNO Care includes HATIV, a chronic disease management platform extending clinical healthcare services to personal health monitoring. The platform analyzes diverse medical data including medical imaging (CT/X-ray/MRI), pathology slides, biosignals (ECG/vital signs), and supports speech processing. Vuno Med products are FDA-approved and deployed in hospitals, while the company is expanding globally into US and European markets.
Differentiator
Problem solved
Functional benefit
Brands
- VUNO Med: Medical AI solutions brand including Chest X-ray, Fundus AI, and DeepCARS products for healthcare professionals
- VUNO Care
- VUNO Med-Chest X-ray
- VUNO Med-Fundus AI
- VUNO Med-DeepCARS
- VUNO Care-HATIV
- DeepCARS
- HATIV
Products and services
- VUNO Med-Chest X-ray AI medical device software that accurately identifies the presence of major abnormal findings in chest X-ray images and pinpoints the suspected location of abnormalities. Sold to hospitals, radiology departments, and healthcare institutions as an FDA-approved and Korea MFDS-cleared AI medical device for clinical decision support.
- VUNO Med-Fundus AI AI medical device software that classifies normal versus abnormal fundus images and detects the presence or absence of 12 common fundus findings. Sold to hospitals, ophthalmology clinics, and healthcare institutions for retinal screening and diagnostic decision support.
- VUNO Med-DeepCARS FDA-approved AI medical device that predicts the risk of cardiac arrest within 24 hours based on patient vital signs including ECG data. Validated in a secondary hospital study demonstrating a 21% reduction in cardiac arrest occurrences. Sold to hospitals and healthcare systems as an Early Warning System for clinical decision support.
- VUNO Care-HATIV Chronic disease total platform service that extends VUNO's medical AI capabilities from the clinical domain into personal health management, integrating ECG measurement, vital sign monitoring (heart rate, blood pressure, blood glucose, body temperature), and symptom tracking for chronic disease patients. Sold directly to individual consumers via VUNO Mall and Naver Smart Store as a subscription or unit-priced personal health device/service.
Quantifiable outcome
- 21% reduction in cardiac arrest occurrences validated in secondary hospital study
- +2 more outcomes
Companies that use Vuno
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Vuno technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
Vuno partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Korean Society of Tuberculosis and Respiratory DiseasescoreVUNO signed an MOU with the Korean Society of Tuberculosis and Respiratory Diseases to strengthen clinical evidence for medical AI. The partnership aims to advance clinical validation and scientific evidence for VUNO's AI diagnostic solutions, particularly VUNO Med-Chest X-ray for tuberculosis and respiratory disease detection.
- Contextflow (Austria)coreVUNO Inc. signed a strategic MOU with Austrian imaging AI company Contextflow to expand the use of VUNO Med-DeepCARS (AI-based cardiac arrest prediction solution) in Europe. The collaboration involves technical integration, clinical validation, and joint go-to-market activities targeting European hospital markets. Contextflow contributes imaging AI expertise and local market access in Austria and broader Europe.
- Mesalvo (Germany)coreVUNO Inc. signed a strategic MOU with German hospital information system provider Mesalvo to expand DeepCARS in Europe. Mesalvo contributes hospital IT system integration capabilities and reimbursement strategy expertise. The partnership aims to reach over 900 hospitals across Europe through technical integration, validation, and reimbursement strategy collaboration.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Vuno competitors and assessment
Company assessmentDirect peers
- Aidoc: Israel-based medical imaging AI company offering AI worklist triage and diagnostic support across CT, X-ray, and MRI — directly comparable to VUNO Med's imaging portfolio for hospital radiology departments.
- Lunit: South Korean medical AI company and the most direct competitor to VUNO, especially in AI chest X-ray (Lunit INSIGHT CXR) and oncology imaging. Closely comparable product set, geography, regulatory profile, and customer base.
- Oxipit: Lithuania-based AI company developing chest X-ray and orthopedic imaging AI products, including autonomous reporting — directly comparable to VUNO Med's X-ray AI offering.
- RapidAI: US-based medical imaging AI company focused on neurovascular and vascular imaging AI — comparable to VUNO in clinical decision-support imaging AI sold to hospital systems, though in a different clinical vertical.
- Annalise.ai: Australia-based AI company offering comprehensive chest X-ray abnormality detection (200+ findings) — direct competitor to VUNO Med-Chest X-ray in the AI triage market.
- Qure.ai: India-headquartered medical imaging AI company competing with VUNO Med-Chest X-ray and VUNO Med-Fundus AI. Direct competitor in chest X-ray triage and head CT/trauma AI, sold globally to hospitals.
Regional players
- Deep Bio: South Korean AI company focused on digital pathology AI for prostate cancer — comparable peer to VUNO in Korean medical AI ecosystem and overlapping digital pathology capability.
- JLK Inspection: South Korean AI healthcare company developing stroke and brain imaging AI — a regional peer to VUNO in the Korean medical AI market and one of the named local players in the same Korea AI healthcare category.
Broad incumbents
- Nanox (Zebra Medical Vision): Global medical imaging company that acquired Zebra Medical Vision — offers AI-driven imaging analytics platform comparable to VUNO Med's imaging portfolio across a broader clinical and hardware-integrated footprint.
Emerging players
- Contextflow: Austrian imaging AI company partnered with VUNO for DeepCARS distribution. Overlaps with VUNO's radiology AI capabilities (CT lung and 3D imaging) and is a meaningful adjacent peer in the EU hospital AI market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Vuno social profiles
Digital presenceVuno compliance and trust
Trust signalCompliance2 records
Vuno financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vuno leadership team
Management profileNumber of profiles
Profiles4 records
Vuno subsidiaries and ownership
Company hierarchySubsidiaries1 record
Vuno funding detail
Funding detailFunding overview
Funding rounds8 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vuno M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vuno
What does Vuno do?
VUNO develops and sells deep learning-based medical AI software products under two brands: VUNO Med (B2B medical device AI for hospitals including Chest X-ray analysis, Fundus AI, and DeepCARS cardiac arrest prediction) and VUNO Care (B2C consumer health platform HATIV for chronic disease management). The company generates revenue through software/device licensing and subscriptions to clinical and consumer health monitoring solutions that analyze medical imaging, biosignals, and digital pathology data.
Is Vuno a public or private company?
Vuno is a private company. It is classified as public and is currently operating.
When was Vuno founded?
Vuno was founded in 2014. It employs 51 to 100 people.
Where is Vuno based?
Vuno is headquartered in Seoul, South Korea, in the Asia region.
How does Vuno make money?
Three revenue lines are on record. VUNO Med (Medical Device AI Software) is the primary driver. The others are VUNO Care - HATIV (Consumer Health Platform) and international Licensing and Partnership Revenue.
Who are Vuno's main competitors?
Direct peers on record are Aidoc, Lunit, Oxipit, RapidAI, Annalise.ai and Qure.ai. Regional players are Deep Bio and JLK Inspection. Nanox (Zebra Medical Vision) is listed as a broad incumbent. Contextflow is listed as an emerging player.
Does Vuno have an API?
No public API is recorded for Vuno.
What industry is Vuno in?
Vuno's product category is Medical AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3841.